These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
97 related items for PubMed ID: 7728127
21. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH. Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340 [Abstract] [Full Text] [Related]
22. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I. Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371 [Abstract] [Full Text] [Related]
23. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Tse JC, Moore TB. Pharmacotherapy; 1998 Oct; 18(5):988-1000. PubMed ID: 9758310 [Abstract] [Full Text] [Related]
26. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD. Wawer A, Laws HJ, Dilloo D, Göbel U, Burdach S. Klin Padiatr; 2004 Oct; 216(3):169-75. PubMed ID: 15175962 [Abstract] [Full Text] [Related]
30. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. Topolsky D, Crilley P, Styler MJ, Bulova S, Brodsky I, Marks DI. Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353 [Abstract] [Full Text] [Related]
31. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A. Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367 [Abstract] [Full Text] [Related]
35. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A. Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290 [Abstract] [Full Text] [Related]
36. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023 [Abstract] [Full Text] [Related]
37. Graft-versus-host disease: how to translate new insights into new therapeutic strategies. Devetten MP, Vose JM. Biol Blood Marrow Transplant; 2004 Dec; 10(12):815-25. PubMed ID: 15570250 [Abstract] [Full Text] [Related]
38. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors]. Hamazaki T, Yagi K, Inoue M, Sakata N, Okamura T, Yasui M, Sasabe M, Kishimoto T, Inoue A, Kawa K. Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106 [Abstract] [Full Text] [Related]